IXICO plc - IXICO announces expanded contract with Vaccinex
("IXICO" or the "Company")
IXICO announces an expanded contract for its imaging services with Vaccinex
Supports Vaccinex's diversification into clinical development of pepinemab for Alzheimer's disease
"This AD trial, called SIGNAL - AD, is part of a new wave of investment in treatments for neurodegeneration by the global biopharmaceutical industry, with additional assets being brought through the pipeline thanks to the insights unlocked in earlier research programmes.
"We are delighted that Vaccinex has chosen to expand our partnership to support its diversification into Alzheimer's disease. Our existing project with Vaccinex, the SIGNAL trial, is in
This contract does not have significant impact on management's expectations of perfomance for the year.
For further information please contact:
| || |
+44 (0) 20 3763 7498
| || |
| || |
+44 (0) 203 950 9144
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.
Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
More information is available on www.IXICO.com
About Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in non-small cell lung cancer and
This information is provided by RNS, the news service of the
Quick facts: IXICO PLC
Market Cap: £31.55 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE